Solving access to lung cancer care across Europe.
作者信息
Brooks Eric D, De Leo Alexandra N
机构信息
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville and Jacksonville, FL, USA.
Premier Radiation Oncology Associates, Clearwater, FL, USA.
出版信息
Lancet Reg Health Eur. 2024 Mar 1;38:100873. doi: 10.1016/j.lanepe.2024.100873. eCollection 2024 Mar.
Abstract
摘要
相似文献
1
Solving access to lung cancer care across Europe.解决全欧洲肺癌治疗的可及性问题。
Lancet Reg Health Eur. 2024 Mar 1;38:100873. doi: 10.1016/j.lanepe.2024.100873. eCollection 2024 Mar.
2
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.可切除非小细胞肺癌的新型全身治疗模式及欧洲各地患者获得治疗的差异。
Lancet Reg Health Eur. 2024 Mar 4;38:100840. doi: 10.1016/j.lanepe.2024.100840. eCollection 2024 Mar.
3
The European initiative for quality management in lung cancer care.欧洲肺癌护理质量管理倡议。
Eur Respir J. 2014 May;43(5):1254-77. doi: 10.1183/09031936.00106913. Epub 2014 Mar 23.
4
Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study.1999 - 2007年欧洲肺癌和胸膜癌的生存模式：EUROCARE - 5研究结果
Eur J Cancer. 2015 Oct;51(15):2242-2253. doi: 10.1016/j.ejca.2015.07.033. Epub 2015 Sep 26.
5
Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe.肿瘤学中的靶向联合治疗：在欧洲，针对单药治疗设计的具有挑战性的监管框架。
Drug Discov Today. 2023 Aug;28(8):103620. doi: 10.1016/j.drudis.2023.103620. Epub 2023 May 16.
6
Primary care physicians' access to in-house ultrasound examinations across Europe: a questionnaire study.欧洲初级保健医生进行内部超声检查的情况：一项问卷调查研究。
BMJ Open. 2019 Sep 30;9(9):e030958. doi: 10.1136/bmjopen-2019-030958.
7
Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide.欧洲和全球系统性红斑狼疮患者获得医疗服务的挑战与机遇。
Rheumatology (Oxford). 2024 Jul 1;63(7):1772-1778. doi: 10.1093/rheumatology/keae227.
8
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.欧洲胸病理实验室针对非小细胞肺癌的真实世界 EGFR 检测实践。
ESMO Open. 2023 Oct;8(5):101628. doi: 10.1016/j.esmoop.2023.101628. Epub 2023 Sep 14.
9
Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017.欧洲和北美的年龄和性别特异性肺癌死亡率趋势：2000 年至 2017 年期间世卫组织死亡率数据库中生命登记数据的分析。
Eur J Cancer. 2022 Aug;171:269-279. doi: 10.1016/j.ejca.2022.05.011. Epub 2022 Jun 20.
10
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.EBCC-14 宣言：解决欧洲转移性乳腺癌患者获得创新治疗机会的差异问题。
Eur J Cancer. 2024 Aug;207:114156. doi: 10.1016/j.ejca.2024.114156. Epub 2024 Jun 7.
本文引用的文献
1
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.可切除非小细胞肺癌的挑战与争议：临床医生视角
Lancet Reg Health Eur. 2024 Mar 1;38:100841. doi: 10.1016/j.lanepe.2024.100841. eCollection 2024 Mar.
2
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.可切除非小细胞肺癌的新型全身治疗模式及欧洲各地患者获得治疗的差异。
Lancet Reg Health Eur. 2024 Mar 4;38:100840. doi: 10.1016/j.lanepe.2024.100840. eCollection 2024 Mar.
3
Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations.医疗保险局限制 FDA 批准产品覆盖范围的权限：法律和政策考虑。
JAMA Intern Med. 2023 Sep 1;183(9):999-1004. doi: 10.1001/jamainternmed.2023.3961.
4
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.医疗保险覆盖了大多数经食品和药物管理局批准的设备和 B 部分药物，但仍存在限制和差异。
Health Aff (Millwood). 2013 Jun;32(6):1109-15. doi: 10.1377/hlthaff.2012.1073.
Zotero 插件